Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 18.884
Filter
3.
Копенгаген; Всемирная организация здравоохранения. Европейское региональное бюро; 2023. (WHO/2019-nCoV/Vaccines/SAGE/Prioritization/2023.1).
in Russian | WHOIRIS | ID: gwh-371051
4.
Bol. micol. (Valparaiso En linea) ; 37(1): 9-18, jun. 2022. tab
Article in Spanish | WHO COVID, LILACS (Americas) | ID: covidwho-20235149

ABSTRACT

Existen múltiples reportes de manifestaciones persistentes en pacientes que cursaron infecciones por SARS-CoV-2, independiente de su gravedad, configurando el síndrome de COVID-19 prolongado. No existe una definición consensuada de este síndrome, cuya patogenia pareciera ser multifactorial. Considerando las más de 500 millones de infecciones en todo el mundo, este síndrome pudiese incidir en una insospechada y prolongada carga sobre los sistemas sanitarios. Reportes recientes han asociado a la vacunación con esquema primario completo como una asociación protectora para el desarrollo de COVID-19 prolongado, transformándose en otro beneficio poblacional asociado a las vacunas.(AU)


There are multiple reports of persistent manifestations in patients who had SARS-CoV-2 infections, regardless of their severity, configuring the prolonged COVID-19 syndrome. There is no agreed definition of this syndrome whose pathogenesis seems to be multifactorial. Considering the more than 500 million infections worldwide, this syndrome could have an unsuspected and prolonged burden on health systems . Recent reports have associated vaccination with a complete primary schedule as a protective association with the development of prolonged COVID-19, becoming another population benefit associated with vaccines.(AU)


Subject(s)
Humans , Post-Acute COVID-19 Syndrome/complications , Post-Acute COVID-19 Syndrome/physiopathology , COVID-19 Vaccines , Post-Acute COVID-19 Syndrome/classification
5.
Med.lab ; 26(4): 319-322, 2022.
Article in Spanish | WHO COVID, LILACS (Americas) | ID: covidwho-20234904

ABSTRACT

Entre finales de 2019 y mediados de 2022, la pandemia de COVID-19 ha causado más de 600 millones de casos confirmados y al menos 6,5 millones de muertes, constituyendo la emergencia de salud pública más importante de las últimas décadas. En paralelo con el transcurso de la pandemia, ha tenido lugar una carrera sin precedentes por la obtención de vacunas eficaces para el control de la rápida dispersión del virus. Cuatro meses después del anuncio de la emergencia del SARS-CoV-2, agente de la pandemia, ya habían 115 "vacunas candidatas", cinco de ellas en fase de ensayos clínicos [1]. Al mismo tiempo, una gran revolución en la producción de vacunas estaba ocurriendo; nuevas tecnologías de producción de biológicos, más eficaces y más rápidas, llevaron al desarrollo de vacunas útiles en un tiempo increíblemente corto. Antes de la pandemia, el desarrollo de una nueva vacuna típicamente solía tomar entre cinco y diez años, pero en 2020, a menos de un año de haberse declarado la pandemia, ya se habían publicado ensayos clínicos que demostraban la eficacia de varias vacunas producidas mediante tecnologías novedosas [2]. Son numerosas las vacunas contra el SARS-CoV-2 que han sido autorizadas para su uso. A la fecha, más de 12 mil millones de dosis de vacunas han sido administradas en el mundo [3]. Se estima que tres dosis de vacunas pueden evitar hasta en un 94 % el riesgo de uso de ventilación mecánica y muerte [4], así mismo, estudios demuestran que el riesgo de mortalidad por COVID-19 en los no vacunados es 25 veces mayor que en los vacunados


Subject(s)
Humans , COVID-19 , Recombinant Proteins , RNA, Messenger , Disease Vectors , COVID-19 Vaccines
6.
Cien Saude Colet ; 26(5): 1885-1898, 2021 May.
Article in Portuguese, English | MEDLINE | ID: covidwho-20243734

ABSTRACT

This article explores the use of spatial artificial intelligence to estimate the resources needed to implement Brazil's COVID-19 immu nization campaign. Using secondary data, we conducted a cross-sectional ecological study adop ting a time-series design. The unit of analysis was Brazil's primary care centers (PCCs). A four-step analysis was performed to estimate the popula tion in PCC catchment areas using artificial in telligence algorithms and satellite imagery. We also assessed internet access in each PCC and con ducted a space-time cluster analysis of trends in cases of SARS linked to COVID-19 at municipal level. Around 18% of Brazil's elderly population live more than 4 kilometer from a vaccination point. A total of 4,790 municipalities showed an upward trend in SARS cases. The number of PCCs located more than 5 kilometer from cell towers was largest in the North and Northeast regions. Innovative stra tegies are needed to address the challenges posed by the implementation of the country's National COVID-19 Vaccination Plan. The use of spatial artificial intelligence-based methodologies can help improve the country's COVID-19 response.


O objetivo deste artigo é analisar o uso da inteligência artificial espacial no contexto da imunização contra COVID-19 para a seleção adequada dos recursos necessários. Trata-se de estudo ecológico de caráter transversal baseado em uma abordagem espaço-temporal utilizando dados secundários, em Unidades Básicas de Saúde do Brasil. Foram adotados quatro passos analíticos para atribuir um volume de população por unidade básica, aplicando algoritmos de inteligência artificial a imagens de satélite. Em paralelo, as condições de acesso à internet móvel e o mapeamento de tendências espaço-temporais de casos graves de COVID-19 foram utilizados para caracterizar cada município do país. Cerca de 18% da população idosa brasileira está a mais de 4 quilômetros de distância de uma sala de vacina. No total, 4.790 municípios apresentaram tendência de agudização de casos de Síndrome Respiratória Aguda Grave. As regiões Norte e Nordeste apresentaram o maior número de Unidades Básicas de Saúde com mais de 5 quilômetros de distância de antenas de celular. O Plano nacional de vacinação requer o uso de estratégias inovadoras para contornar os desafios do país. O uso de metodologias baseadas em inteligência artificial espacial pode contribuir para melhoria do planejamento das ações de resposta à COVID-19.


Subject(s)
COVID-19 Vaccines , COVID-19 , Aged , Artificial Intelligence , Brazil , Cities , Cross-Sectional Studies , Humans , Intelligence , SARS-CoV-2 , Vaccination
8.
Blood Cancer Discov ; 2(1): 13-18, 2021 01.
Article in English | MEDLINE | ID: covidwho-20238332

ABSTRACT

Cancer vaccine development has been historically fraught with difficulty, but tremendous progress has been made over the past 5 years. In this In Focus article, we reflect on the progress and challenges with vaccine development for cancers in general and for hematologic malignancies in particular, and suggest how our cancer vaccine experience can offer insight into COVID-19 vaccination.


Subject(s)
COVID-19 , Cancer Vaccines , Neoplasms , COVID-19 Vaccines , Humans , Neoplasms/prevention & control , SARS-CoV-2 , Vaccine Development
9.
Cien Saude Colet ; 26(11): 5599-5614, 2021 Nov.
Article in Portuguese, English | MEDLINE | ID: covidwho-20237516

ABSTRACT

The evaluation of vaccine effectiveness is conducted with real-world data. They are essential to monitor the performance of vaccination programmes over time, and in the context of the emergence of new variants. Until now, the effectiveness of COVID-19 vaccines has been assessed based on classic methods, such as cohort and test-negative case-control studies, which may often not allow for adequate control of inherent biases in the assignment of vaccination campaigns. The aim of this review was to discuss the study designs available to evaluate vaccine effectiveness, highlighting quasi-experimental studies, which seek to mimic randomized trials, by introducing an exogenous component to allocate to treatment, in addition to the advantages, limitations, and applicability in the context of Brazilian data. The use of quasi-experimental approaches, such as interrupted time series, difference-in-differences, propensity scores, instrumental variables, and regression discontinuity design, are relevant due to the possibility of providing more accurate estimates of COVID-19 vaccine effectiveness. This is especially important in scenarios such as the Brazilian, which characterized by the use of various vaccines, with the respective numbers and intervals between doses, applied to different age groups, and introduced at different times during the pandemic.


A avalição da efetividade de vacinas é feita com dados do mundo real e é essencial para monitorar o desempenho dos programas de vacinação ao longo do tempo bem como frente a novas variantes. Até o momento, a avaliação da efetividade das vacinas para COVID-19 tem sido baseada em métodos clássicos como estudos de coorte e caso controle teste-negativo, que muitas vezes podem não permitir o adequado controle dos vieses intrínsecos da alocação das campanhas de vacinação. O objetivo dessa revisão foi discutir os desenhos de estudo disponíveis para avaliação de efetividade das vacinas, enfatizando os estudos quase-experimentais, que buscam mimetizar os estudos aleatorizados ao introduzir um componente exógeno para atribuição ao tratamento, bem como suas vantagens, limitações e aplicabilidade no contexto dos dados brasileiros. O emprego de métodos quase-experimentais, incluindo as séries temporais interrompidas, o método de diferença em diferenças, escore de propensão, variáveis instrumentais e regressão descontínua, são relevantes pela possibilidade de gerar estimativas mais acuradas da efetividade de vacinas para COVID-19 em cenários como o brasileiro, que se caracteriza pelo uso de várias vacinas, com respectivos número e intervalos entre doses, aplicadas em diferentes faixas etárias e em diferentes momentos da pandemia.


Subject(s)
COVID-19 , Vaccines , COVID-19 Vaccines , Humans , SARS-CoV-2
11.
J Prev Med Public Health ; 56(3): 221-230, 2023 May.
Article in English | MEDLINE | ID: covidwho-20241661

ABSTRACT

OBJECTIVES: The second wave of coronavirus disease 2019 (COVID-19) cases in Indonesia, during which the Delta variant predominated, took place after a vaccination program had been initiated in the country. This study was conducted to assess the impact of COVID-19 vaccination on unfavorable clinical outcomes including hospitalization, severe COVID-19, intensive care unit (ICU) admission, and death using a real-world model. METHODS: This single-center retrospective cohort study involved patients with COVID-19 aged ≥18 years who presented to the COVID-19 emergency room at a secondary referral teaching hospital between June 1, 2021 and August 31, 2021. We used a binary logistic regression model to assess the effect of COVID-19 vaccination on unfavorable clinical outcomes, with age, sex, and comorbidities as confounding variables. RESULTS: A total of 716 patients were included, 32.1% of whom were vaccinated. The elderly participants (≥65 years) had the lowest vaccine coverage among age groups. Vaccination had an effectiveness of 50% (95% confidence interval [CI], 25 to 66) for preventing hospitalization, 97% (95% CI, 77 to 99) for preventing severe COVID-19, 95% (95% CI, 56 to 99) for preventing ICU admission, and 90% (95% CI, 22 to 99) for preventing death. Interestingly, patients with type 2 diabetes had a 2-fold to 4-fold elevated risk of unfavorable outcomes. CONCLUSIONS: Among adults, COVID-19 vaccination has a moderate preventive impact on hospitalization but a high preventive impact on severe COVID-19, ICU admission, and death. The authors suggest that relevant parties increase COVID-19 vaccination coverage, especially in the elderly population.


Subject(s)
COVID-19 , Diabetes Mellitus, Type 2 , Adult , Humans , Aged , Adolescent , Indonesia/epidemiology , COVID-19 Vaccines/therapeutic use , Retrospective Studies , Secondary Care Centers , COVID-19/epidemiology , COVID-19/prevention & control , SARS-CoV-2 , Vaccination , Hospitalization
12.
Can J Surg ; 66(3): E304-E309, 2023.
Article in English | MEDLINE | ID: covidwho-20241614

ABSTRACT

BACKGROUND: In a large nationwide mass vaccination setting, the SARS-CoV-2 vaccine was recently linked to myocarditis, lymphadenopathy, herpes zoster infection and appendicitis. We aimed to examine the characteristics and management of SARS-CoV-2 vaccine-related acute appendicitis. METHODS: We performed a retrospective cohort study in a large tertiary medical centre in Israel. All patients presenting with acute appendicitis within 21 days of receiving their SARS-CoV-2 vaccination (PCVAA group) were compared with patients who presented with acute appendicitis not related to the vaccination (N-PCVAA group). RESULTS: We reviewed the records of 421 patients with acute appendicitis from December 2020 to September 2021; 38 (9%) patients presented with acute appendicitis within 21 days of receiving their SARS-CoV-2 vaccination. Patients in the PCVAA group were older than those in the N-PCVAA group (mean 41 ± 19 yr v. 33 ± 15 yr, respectively, p = 0.008), with male predominance. More patients were managed nonsurgically during the pandemic than before the pandemic (24% v. 18%, p = 0.03). CONCLUSION: With the exception of older age, the clinical characteristics of patients presenting with acute appendicitis within 21 days of receiving the SARS-CoV-2 vaccination did not differ from those of patients who presented with acute appendicitis not related to the vaccination. This finding suggests that vaccine-related acute appendicitis is similar to "classic" acute appendicitis.


Subject(s)
Appendicitis , COVID-19 Vaccines , COVID-19 , Female , Humans , Male , Acute Disease , Appendicitis/etiology , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Retrospective Studies , SARS-CoV-2
13.
Int J Environ Res Public Health ; 20(10)2023 05 12.
Article in English | MEDLINE | ID: covidwho-20241601

ABSTRACT

Popular social media platforms, such as Twitter, have become an excellent source of information with their swift information dissemination. Individuals with different backgrounds convey their opinions through social media platforms. Consequently, these platforms have become a profound instrument for collecting enormous datasets. We believe that compiling, organizing, exploring, and analyzing data from social media platforms, such as Twitter, can offer various perspectives to public health organizations and decision makers in identifying factors that contribute to vaccine hesitancy. In this study, public tweets were downloaded daily from Tweeter using the Tweeter API. Before performing computation, the tweets were preprocessed and labeled. Vocabulary normalization was based on stemming and lemmatization. The NRCLexicon technique was deployed to convert the tweets into ten classes: positive sentiment, negative sentiment, and eight basic emotions (joy, trust, fear, surprise, anticipation, anger, disgust, and sadness). t-test was used to check the statistical significance of the relationships among the basic emotions. Our analysis shows that the p-values of joy-sadness, trust-disgust, fear-anger, surprise-anticipation, and negative-positive relations are close to zero. Finally, neural network architectures, including 1DCNN, LSTM, Multiple-Layer Perceptron, and BERT, were trained and tested in a COVID-19 multi-classification of sentiments and emotions (positive, negative, joy, sadness, trust, disgust, fear, anger, surprise, and anticipation). Our experiment attained an accuracy of 88.6% for 1DCNN at 1744 s, 89.93% accuracy for LSTM at 27,597 s, while MLP achieved an accuracy of 84.78% at 203 s. The study results show that the BERT model performed the best, with an accuracy of 96.71% at 8429 s.


Subject(s)
COVID-19 , Social Media , Humans , Sentiment Analysis , COVID-19 Vaccines , Public Health , COVID-19/prevention & control , Data Mining , Neural Networks, Computer , Vaccination
14.
BMJ Glob Health ; 8(6)2023 Jun.
Article in English | MEDLINE | ID: covidwho-20241519

ABSTRACT

Although significant progress has been made in achieving goals for COVID-19 vaccine access, the quest for equity and justice remains an unfinished agenda. Vaccine nationalism has prompted calls for new approaches to achieve equitable access and justice not only for vaccines but also for vaccination. This includes ensuring country and community participation in global discussions and that local needs to strengthen health systems, address issues related to social determinants of health, build trust and leverage acceptance to vaccines, are addressed. Regional vaccine technology and manufacturing hubs are promising approaches to address access challenges and must be integrated with efforts to ensure demand. The current situation underlines the need for access, demand and system strengthening to be addressed along with local priorities for justice to be achieved. Innovations to improve accountability and leverage existing platforms are also needed. Sustained political will and investment is required to ensure ongoing production of non-pandemic vaccines and sustained demand, particularly when perceived threat of disease appears to be waning. Several recommendations are made to govern towards justice including codesigning the path forward with low-income and middle-income countries; establishing stronger accountability measures; establishing dedicated groups to engage with countries and manufacturing hubs to ensure that the affordable supply and predictable demand are in balance; addressing country needs for health system strengthening through leveraging existing health and development platforms and delivering on product presentations informed by country needs. Even if difficult, we must converge on a definition of justice well in advance of the next pandemic.


Subject(s)
COVID-19 , Vaccines , Humans , COVID-19 Vaccines , COVID-19/prevention & control , Vaccination , Social Justice
15.
Methods Mol Biol ; 2673: 371-399, 2023.
Article in English | MEDLINE | ID: covidwho-20241347

ABSTRACT

Structure-based vaccine design (SBVD) is an important technique in computational vaccine design that uses structural information on a targeted protein to design novel vaccine candidates. This increasing ability to rapidly model structural information on proteins and antibodies has provided the scientific community with many new vaccine targets and novel opportunities for future vaccine discovery. This chapter provides a comprehensive overview of the status of in silico SBVD and discusses the current challenges and limitations. Key strategies in the field of SBVD are exemplified by a case study on design of COVID-19 vaccines targeting SARS-CoV-2 spike protein.


Subject(s)
COVID-19 , Humans , COVID-19/prevention & control , SARS-CoV-2 , COVID-19 Vaccines , Spike Glycoprotein, Coronavirus , Molecular Docking Simulation
16.
Orv Hetil ; 164(21): 803-810, 2023 May 28.
Article in Hungarian | MEDLINE | ID: covidwho-20241140

ABSTRACT

INTRODUCTION: In Hungary, regarding the age-related mandatory vaccinations, the population is almost 100% vaccinated. In the case of recommended vaccinations, however, the situation is less favourable, and during the COVID-19 pandemic, anti-vaccination sentiment has also appeared in some groups to a greater extent than before. Reducing this is the task of all health professionals. OBJECTIVE: The exploration of knowledge and attitudes about vaccinations, and the analysis of the characteristics of these factors according to gender, year and vaccine willingness/hesitancy among medical students at the University of Szeged. METHOD: The cross-sectional study was conducted among first and fourth year medical students of the University, using an online questionnaire, which examined, in addition to sociodemographic characteristics, the administration of influenza and COVID-19 vaccinations, the self-assessment of knowledge about vaccinations, the importance of vaccinations, and student opinions about recommended vaccinations. RESULTS: Based on the definition of the WHO Strategic Advisory Group, 88.6% of the students belonged to the "vaccine willingness" group, who administered the vaccine against COVID-19 as soon as it became available, while the "vaccine hesitancy" group (11.4%) only asked for the vaccine when vaccination was made mandatory or not even then. According to the model adjusted to gender and year, those who showed willingness to vaccinate were more likely to consider the use of vaccinations, counselling, etc. important than those who were hesitant, while there was no correlation with the self-rating of knowledge. On the basis of the odds ratio of the statements related to the recommended vaccinations, it was possible to identify the opinions associated with vaccine willingness or hesitancy. DISCUSSION: Overall, student knowledge and attitudes showed a positive picture. On the other hand, it should be emphasized that the misconceptions identified among students showing vaccine hesitancy are the same as the anti-vaccination sentiments found among the general population. CONCLUSION: During university training, more emphasis should be placed on monitoring the willingness of students to be vaccinated, and on developing knowledge and communication. Orv Hetil. 2023; 164(21): 803-810.


Subject(s)
COVID-19 , Students, Medical , Humans , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines , Cross-Sectional Studies , Pandemics , Vaccination , Attitude , Health Knowledge, Attitudes, Practice
17.
Rheumatol Int ; 43(9): 1621-1627, 2023 Sep.
Article in English | MEDLINE | ID: covidwho-20241087

ABSTRACT

OBJECTIVES: To characterize the antibody response to COVID-19 mRNA vaccination in patients with Systemic Lupus Erythematosus (SLE) and identify predictors of poor response. METHODS: SLE patients who are followed at the Beth Israel Deaconess Medical Center Lupus Cohort (BID-LC) were enrolled. SARS-CoV-2 IgG Spike antibody was measured in patients who received two doses of either the BNT162b2 (Pfizer-BioNTech) or the mRNA-1273 (Moderna) COVID-19 vaccine (n = 62). We defined non-responders as patients with an IgG Spike antibody titer less than two-fold (< 2) the index value of the test and responders as patients with antibody levels greater or equal to two-fold (≥ 2). A web-based survey was used to collect information regarding immunosuppressive medication use and SLE flares after vaccination. RESULTS: In our cohort of lupus patients, 76% were vaccine responders. The use of two or more immunosuppressive drugs was associated with being a non-responder (Odds Ratio 5.26; 95% CI 1.23-22.34, p = 0.02). Both Belimumab use and higher Prednisone dose were associated with vaccine non-response (p = 0.04 and p = 0.04). The non-responder group had higher mean levels of serum IL-18 than the responder group (p = 0.04) as well as lower C3 levels (p = 0.01). Lupus flares and breakthrough infections were uncommon post-vaccination. CONCLUSIONS: Immunosuppressive medications have a negative impact on vaccine humoral response in SLE individuals. We observed a trend towards vaccine no-response in BNT162b2 recipients and a relationship between IL-18 and impaired antibody response that merits further investigation.


Subject(s)
COVID-19 , Lupus Erythematosus, Systemic , Humans , COVID-19 Vaccines , BNT162 Vaccine , Interleukin-18 , Antibody Formation , COVID-19/prevention & control , SARS-CoV-2 , Antibodies, Viral , Immunoglobulin G , Vaccination
18.
J Neonatal Perinatal Med ; 16(2): 235-237, 2023.
Article in English | MEDLINE | ID: covidwho-20240921

ABSTRACT

INTRODUCTION: The coronavirus disease (COVID-19) has created a serious health problem in pregnant people. We aimed to address whether vaccination can prevent development of placental disease in SARS-CoV-2 infected mothers. METHODS: We reported the pathology findings obtained from routine histopathological examination of placentas of overall 38 cases. RESULTS: We found low prevalence of placental pathology in vaccinated pregnant people with active SARS-CoV-2 infection in comparison to those unvaccinated cases. CONCLUSION: Based on our findings, SARS-CoV-2 vaccination can prevent development of placental pathological lesions and may lower the risk of serious illness in pregnant people.


Subject(s)
COVID-19 , Pregnancy Complications, Infectious , Pregnancy , Humans , Female , Placenta , SARS-CoV-2 , COVID-19/prevention & control , COVID-19 Vaccines/therapeutic use , Vaccination , Pregnancy Complications, Infectious/prevention & control , Infectious Disease Transmission, Vertical/prevention & control
19.
Viruses ; 15(5)2023 05 13.
Article in English | MEDLINE | ID: covidwho-20240840

ABSTRACT

The humoral response after vaccination was evaluated in 1248 individuals who received different COVID-19 vaccine schedules. The study compared subjects primed with adenoviral ChAdOx1-S (ChAd) and boosted with BNT162b2 (BNT) mRNA vaccines (ChAd/BNT) to homologous dosing with BNT/BNT or ChAd/ChAd vaccines. Serum samples were collected at two, four and six months after vaccination, and anti-Spike IgG responses were determined. The heterologous vaccination induced a more robust immune response than the two homologous vaccinations. ChAd/BNT induced a stronger immune response than ChAd/ChAd at all time points, whereas the differences between ChAd/BNT and BNT/BNT decreased over time and were not significant at six months. Furthermore, the kinetic parameters associated with IgG decay were estimated by applying a first-order kinetics equation. ChAd/BNT vaccination was associated with the longest time of anti-S IgG negativization and with a slow decay of the titer over time. Finally, analyzing factors influencing the immune response by ANCOVA analysis, it was found that the vaccine schedule had a significant impact on both the IgG titer and kinetic parameters, and having a Body Mass Index (BMI) above the overweight threshold was associated with an impaired immune response. Overall, the heterologous ChAd/BNT vaccination may offer longer-lasting protection against SARS-CoV-2 than homologous vaccination strategies.


Subject(s)
COVID-19 Vaccines , COVID-19 , Humans , Longitudinal Studies , BNT162 Vaccine , COVID-19/prevention & control , SARS-CoV-2 , Vaccination , ChAdOx1 nCoV-19 , Immunoglobulin G , Antibodies, Viral , Antibodies, Neutralizing
20.
J Clin Ethics ; 34(2): 158-168, 2023.
Article in English | MEDLINE | ID: covidwho-20240773

ABSTRACT

AbstractAs we journey into the fourth year of the COVID-19 pandemic, a majority of Americans express relief at a "return to normal," experience pandemic fatigue, or embrace the idea of living with COVID-19 in much the same way we live with the seasonal flu. But transition to a new phase of life with SARS-CoV-2 does not diminish the importance of vaccination. The US Centers for Disease Control and the Food and Drug Administration recently recommended another round of booster dose for persons age 5 and up, or an initial series for those not previously vaccinated, with an updated bivalent formula that protects against both the original virus strain and Omicron subvariants that are now the dominant source of infection. By most accounts most of the population has been or will become infected with SARS-CoV-2. Suboptimal uptake of the COVID-19 vaccines among the approximately 25 million adolescents in the United States is a significant obstacle to population coverage, public health, and the health and well-being of adolescents. A major cause of low adolescent uptake is parental vaccine hesitancy. This article discusses parental vaccine hesitancy and argues that permitting independent adolescent consent to COVID-19 vaccination should be an ethical and policy priority as we continue to confront the threat of Omicron and other variants of the coronavirus. We discuss the central role of the pediatric healthcare team in caring for adolescent patients who disagree with their parents about vaccination.


Subject(s)
COVID-19 , Humans , Adolescent , Child , Child, Preschool , COVID-19/prevention & control , COVID-19 Vaccines , Pandemics/prevention & control , SARS-CoV-2 , Vaccination Hesitancy , Vaccination , Parents
SELECTION OF CITATIONS
SEARCH DETAIL